Bay­er is blue­print­ing a new pro­duc­tion fa­cil­i­ty to add to its cam­pus in the Bay Area with a $150 mil­lion bud­get to com­plete the task.

Pro­posed Bay­er Plant Bay­er Click on the im­age to see the full-sized ver­sion

On Thurs­day the com­pa­ny an­nounced that it will build a be­spoke 40,000-square-foot fa­cil­i­ty on its Berke­ley cam­pus, where they al­ready pro­duce he­mo­phil­ia A prod­ucts. The plan is to add on clin­i­cal pro­duc­tion op­er­a­tions at the new Cell Cul­ture Tech­nol­o­gy Cen­ter to sup­port their drug re­search work in on­col­o­gy, car­di­ol­o­gy and some oth­er spe­cial­ty health en­deav­ors.

“This in­vest­ment al­lows Bay­er to ex­pand our bi­o­log­ics de­vel­op­ment and launch ca­pa­bil­i­ties, as we ad­vance our R&D pro­grams in­ter­nal­ly and through strate­gic col­lab­o­ra­tions,” said Wol­fram Car­ius, head of Bay­er Phar­ma­ceu­ti­cals Prod­uct Sup­ply.

You can look for it to come on line in 2021.